Skip to main content
SpringerLink
Log in

A cost-effectiveness study* has added fuel to the debate over the UK's decision to restrict cholinesterase inhibitor use to moderate Alzheimer's disease (AD)

  • Non-clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Maclaine G, Getsios D, Blume S, Ishak J.Updated cost-effectiveness projections for donepezil in the treatment of patients with mild to moderately severe Alzheimer's disease in the UK. 2009 International Conference on Alzheimer's Disease: abstr. P3-224, 13 Jul 2009. Available from: URL: http://www.alz.org

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

A cost-effectiveness study* has added fuel to the debate over the UK's decision to restrict cholinesterase inhibitor use to moderate Alzheimer's disease (AD). Pharmacoecon. Outcomes News 584, 5 (2009). https://doi.org/10.2165/00151234-200905840-00013

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905840-00013

Keywords

Search

Navigation